Latest Regulatory Change News

Kingfish Limited posted a $13.6 million net loss for the year ended 31 March 2026, with portfolio returns lagging the benchmark amid geopolitical tensions and AI sector uncertainty.

Centuria Capital Group launches a $300 million fully underwritten equity raise to accelerate its AI Factory pipeline via ResetData and expand its real estate and credit funds platform.

EDU Holdings lifted total student enrolments by 32% in Trimester 2 2026, driven by strong growth at its higher education arm Ikon Institute, offsetting softness in its vocational training division.

Eureka Group Holdings (ASX: EGH) expects FY26 underlying EBITDA to meet or exceed $21.1 million, driven by seniors’ occupancy above 97% and rent growth exceeding 6%. Capital recycling and a robust acquisition pipeline support growth.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Barramundi Limited’s May update reveals a 2.3% adjusted NAV decline, weighed down by CSL’s earnings downgrade and Brambles’ operational setbacks, despite positive contributions from Xero and Credit Corp.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Macallum New Energy has expanded its exploration prospects in the underexplored southern North Perth Basin with a new oil and gas prospect, Aberfeldy, and plans to pursue helium and hydrogen exploration following recent regulatory changes.

Elsight has secured a follow-on US$2 million order from a U.S. public safety customer, quadrupling its initial purchase and underscoring growing commercial traction ahead of expected FAA drone rule changes.

Bridge SaaS Limited (ASX: BGE) is issuing nearly 20 million Loyalty Options to reward shareholders, exercisable at $0.03 and expiring in 2031, aiming to bolster future capital without immediate dilution.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Metro Performance Glass has significantly improved its financial footing in FY26, cutting net debt by more than half and boosting EBITDA before significant items to $18.2 million despite subdued markets in New Zealand and Australia.